Base de dados : LILACS
Pesquisa : D03.633.100.473 [Categoria DeCS]
Referências encontradas : 68 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 68 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-794674
Autor: Coelho, Rafael Corrêa; Reinert, Tomás; Campos, Franz; Peixoto, Fábio Affonso; Andrade, Carlos Augusto de; Castro, Thalita; Herchenhorn, Daniel.
Título: Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
Fonte: Int. braz. j. urol;42(4):694-703, July-Aug. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: The aim of this study was to assess the impact of sunitinib treatment in a non-screened group of patients with metastatic renal cell cancer (mRCC) treated by the Brazilian Unified Health System (SUS) at a single reference institution. Material and Methods: Retrospective cohort study, which evaluated patients with mRCC who received sunitinib between May 2010 and December 2013. Results: Fifty-eight patients were eligible. Most patients were male 41 (71%), with a median age of 58 years. Nephrectomy was performed in 41 (71%) patients with a median interval of 16 months between the surgery and initiation of sunitinib. The most prevalent histological subtype was clear cell carcinoma, present in 52 (91.2%) patients. In 50 patients (86%), sunitinib was the first line of systemic treatment. The main adverse effects were fatigue (57%), hypothyroidism (43%), mucositis (33%) and diarrhea (29%). Grade 3 and 4 adverse effects were infrequent: fatigue (12%), hypertension (12%), thrombocytopenia (7%), neutropenia (5%) and hand-foot syndrome (5%). Forty percent of patients achieved a partial response and 35% stable disease, with a disease control rate of 75%. Median progression free survival was 7.6 months and median overall survival was 14.1 months. Conclusion: Sunitinib treatment was active in the majority of patients, especially those with low and intermediate risk by MSKCC score, with manageable toxicity. Survival rates were inferior in this non-screened population with mRCC treated in the SUS.
Descritores: Pirróis/uso terapêutico
Carcinoma de Células Renais/tratamento farmacológico
Indóis/uso terapêutico
Neoplasias Renais/tratamento farmacológico
Antineoplásicos/uso terapêutico
-Pirróis/efeitos adversos
Brasil
Carcinoma de Células Renais/secundário
Estudos Retrospectivos
Intervalo Livre de Doença
Sunitinibe
Programas Governamentais
Indóis/efeitos adversos
Neoplasias Renais/patologia
Neoplasias Pulmonares/secundário
Metástase Linfática
Pessoa de Meia-Idade
Programas Nacionais de Saúde
Antineoplásicos/efeitos adversos
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Adulto Jovem
Responsável: BR1.1 - BIREME


  2 / 68 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-954052
Autor: Demir, Mehmet; Akin, Yigit; Terim, Kubra Asena Kapakin; Gulum, Mehmet; Buyukfirat, Evren; Ciftci, Halil; Yeni, Ercan.
Título: Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study
Fonte: Int. braz. j. urol;44(3):600-607, May-June 2018. tab, graf.
Idioma: en.
Projeto: Harran University Scientific Research and Projects Unit.
Resumo: ABSTRACT Objectives: Apoptosis effect of oral alpha-blockers is known in the prostate. Apoptosis index of silodosin has not been proved, yet. Aims are to present apoptosis index of silodosin in prostate and to compare this with other currently used alpha-blocker's apoptosis indexes together with their clinical effects. Materials and Methods: Benign prostatic hyperplasia (BPH) patients were enrolled among those admitted to urology outpatient clinic between June 2014 and June 2015. Study groups were created according to randomly prescribed oral alpha-blocker drugs as silodosin 8mg (Group 1; n=24), tamsulosin 0.4mg (Group 2; n=30), alfuzosin 10mg (Group 3; n=25), doxazosin 8mg (Group 4; n=22), terazosin 5mg (Group 5; n=15). Pa- tients who refused to use any alpha-blocker drug were included into Group 6 as control group (n=16). We investigated apoptosis indexes of the drugs in prostatic tissues that were taken from patient's surgery (transurethral resection of prostate) and/or prostate biopsies. Immunochemical dyeing, light microscope, and Image Processing and Analy- sis in Java were used for evaluations. Statistical significant p was p<0.05. Results: There were 132 patients with mean follow-up of 4.2±2.1 months. Pathologist researched randomly selected 10 areas in each microscope set. Group 1 showed statisti- cal significant difference apoptosis index in immunochemical TUNEL dyeing and im- age software (p<0.001). Moreover, we determined superior significant development in parameters as uroflowmetry, quality of life scores, and international prostate symptom score in Group 1. Conclusions: Silodosin has higher apoptosis effect than other alpha-blockers in prostate. Thus, clinic improvement with silodosin was proved by histologic studies. Besides, static factor of BPH may be overcome with creating apoptosis.
Descritores: Próstata/efeitos dos fármacos
Próstata/patologia
Hiperplasia Prostática/patologia
Hiperplasia Prostática/tratamento farmacológico
Apoptose/efeitos dos fármacos
Antagonistas de Receptores Adrenérgicos alfa 1/farmacologia
-Quinazolinas/farmacologia
Valores de Referência
Sulfonamidas/farmacologia
Fatores de Tempo
Biópsia
Prazosina/análogos & derivados
Prazosina/farmacologia
Imuno-Histoquímica
Projetos Piloto
Estudos Retrospectivos
Resultado do Tratamento
Antígeno Prostático Específico/sangue
Doxazossina/farmacologia
Tansulosina
Indóis/farmacologia
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  3 / 68 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-950729
Autor: Matei, Clara; Tampa, Mircea; Caruntu, Constantin; Ion, Rodica-Mariana; Georgescu, Simona-Roxana; Dumitrascu, Georgiana Roxana; Constantin, Carolina; Neagu, Monica.
Título: Protein microarray for complex apoptosis monitoring of dysplastic oral keratinocytes in experimental photodynamic therapy
Fonte: Biol. Res;47:1-9, 2014. ilus, graf.
Idioma: en.
Projeto: Research Projects.
Resumo: BACKGROUND: Photodynamic therapy is an alternative treatment of muco-cutaneous tumors that uses a light source able to photoactivate a chemical compound that acts as a photosensitizer. The phthalocyanines append to a wide chemical class that encompasses a large range of compounds; out of them aluminium-substituted disulphonated phthalocyanine possesses a good photosensitizing potential. RESULTS: The destructive effects of PDT with aluminium-substituted disulphonated phthalocyanine are achieved by induction of apoptosis in tumoral cells as assessed by flow cytometry analysis. Using protein microarray we evaluate the possible molecular pathways by which photodynamic therapy activates apoptosis in dysplastic oral keratinocytes cells, leading to the tumoral cells destruction. Among assessed analytes, Bcl-2, P70S6K kinase, Raf-1 and Bad proteins represent the apoptosis related biomolecules that showed expression variations with the greatest amplitude. CONCLUSIONS: Up to date, the intimate molecular apoptotic mechanisms activated by photodynamic therapy with this type of phthalocyanine in dysplastic human oral keratinocytes are not completely elucidated. With protein microarray as high-throughput proteomic approach a better understanding of the manner in which photodynamic therapy leads to tumoral cell destruction can be obtained, by depicting apoptotic molecules that can be potentially triggered in future anti-tumoral therapies.
Descritores: Fotoquimioterapia
Lesões Pré-Cancerosas/tratamento farmacológico
Neoplasias Bucais/tratamento farmacológico
Queratinócitos/efeitos dos fármacos
Apoptose/efeitos dos fármacos
Análise Serial de Proteínas
-Compostos Organometálicos/uso terapêutico
Lesões Pré-Cancerosas/patologia
Radiossensibilizantes/uso terapêutico
Neoplasias Bucais/patologia
Queratinócitos/patologia
Proteínas Proto-Oncogênicas c-bcl-2/análise
Proteínas Proto-Oncogênicas c-raf/análise
Proteínas Quinases S6 Ribossômicas 70-kDa/análise
Linhagem Celular Tumoral
Proteína de Morte Celular Associada a bcl/análise
Citometria de Fluxo
Indóis/uso terapêutico
Limites: Humanos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: CL1.1 - Biblioteca Central


  4 / 68 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1151056
Autor: Franco, Juan Victor Ariel.
Título: Nueva interacción potencialmente peligrosa entre claritromicina y estatinas / Potentially dangerous interaction between clarithromycin and statins
Fonte: Evid. actual. práct. ambul;19(3):90-90, 2016.
Idioma: es.
Descritores: Claritromicina/efeitos adversos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Inibidores do Citocromo P-450 CYP3A/efeitos adversos
-Pirimidinas/metabolismo
Pirimidinas/uso terapêutico
Pirimidinas/farmacocinética
Rabdomiólise/induzido quimicamente
Sulfonamidas/metabolismo
Sulfonamidas/uso terapêutico
Sulfonamidas/farmacocinética
Ácidos Graxos Monoinsaturados/metabolismo
Ácidos Graxos Monoinsaturados/uso terapêutico
Ácidos Graxos Monoinsaturados/farmacocinética
Pravastatina/metabolismo
Pravastatina/uso terapêutico
Pravastatina/farmacocinética
Inibidores de Hidroximetilglutaril-CoA Redutases/metabolismo
Transportadores de Ânions Orgânicos
Transportadores de Ânions Orgânicos Sódio-Independentes/antagonistas & inibidores
Transportador 1 de Ânion Orgânico Específico do Fígado
Interações Medicamentosas
Injúria Renal Aguda/induzido quimicamente
Rosuvastatina Cálcica
Fluorbenzenos/metabolismo
Fluorbenzenos/uso terapêutico
Fluorbenzenos/farmacocinética
Membro 1B3 da Família de Transportadores de Ânion Orgânico Carreador de Soluto
Fluvastatina
Hiperpotassemia/induzido quimicamente
Indóis/metabolismo
Indóis/uso terapêutico
Indóis/farmacocinética
Limites: Humanos
Masculino
Feminino
Idoso
Idoso de 80 Anos ou mais
Tipo de Publ: Comentário
Responsável: AR2.1 - Biblioteca Central


  5 / 68 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-838413
Autor: Canu, Letizia; Pradella, Silvia; Rapizzi, Elena; Fucci, Rossella; Valeri, Andrea; Briganti, Vittorio; Giachè, Valentino; Parenti, Gabriele; Ercolino, Tonino; Mannelli, Massimo.
Título: Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature
Fonte: Arch. endocrinol. metab. (Online);61(1):90-97, Jan.-Feb. 2017. tab, graf.
Idioma: en.
Resumo: SUMMARY Metastatic pheochromocytomas (PHEOs) and paragangliomas (sPGLs) are rare neural crest-derived tumors with a poor prognosis. About 50% of them are due to germ-line mutations of the SDHB gene. At present, there is no cure for these tumors. Their therapy is palliative and represented by different options among which antiangiogenic drugs, like sunitinib, have been hypothesized to be effective especially in malignant SDHB mutated tumors. We report the effects of sunitinib therapy in a SDHB mutation carrier affected by a malignant sPGL. During 101 weeks of therapy at different doses, sunitinib was able to cause a partial response and then a stable disease for a total of 78 weeks. This favorable response is the longest, out of the 35 so far reported in the literature, registered in a patient treated exclusively with sunitinib but, similarly to the other responses, the effect was limited in time. From our analysis of the scanty data present in the literature, the effect of sunitinib does not seem to be different among wild-type patients and those carrying a cluster 1 germ-line mutation. Sunitinib seems able to slow the disease progression in some patients with malignant PHEO/PGL and therefore may represent a therapeutic option, although randomized controlled studies are needed to assess its efficacy definitively in the treatment of these aggressive tumors.
Descritores: Paraganglioma/tratamento farmacológico
Pirróis/uso terapêutico
Inibidores da Angiogênese/uso terapêutico
Indóis/uso terapêutico
Mutação/genética
Antineoplásicos/uso terapêutico
-Paraganglioma/genética
Paraganglioma/irrigação sanguínea
Succinato Desidrogenase/genética
Resultado do Tratamento
Sunitinibe
Metástase Neoplásica
Limites: Humanos
Masculino
Adulto
Tipo de Publ: Relatos de Casos
Revisão
Responsável: BR1.1 - BIREME


  6 / 68 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887589
Autor: Valdes-Socin, Hernan; Almanza, Matilde Rubio; Fernández-Ladreda, Mariana Tomé; Daele, Daniel Van; Polus, Marc; Chavez, Marcela; Beckers, Albert.
Título: Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor
Fonte: Arch. endocrinol. metab. (Online);61(5):506-509, Sept.-Oct. 2017. graf.
Idioma: en.
Resumo: SUMMARY Neuroendocrine tumors (NETs) can secrete hormones, including ectopic secretions, but they have been rarely associated with malignant hypercalcemia. A 52-year-old man with a history of diabetes mellitus was diagnosed with a pancreatic tumor. A pancreatic biopsy confirmed a well-differentiated pancreatic NET (pNET). The patient subsequently developed liver metastasis and hypercalcemia with high 1,25 OH vitamin D and suppressed parathyroid hormone (PTH) levels. Hypercalcemia was refractory to chemotherapy, intravenous saline fluids, diuretics, calcitonin and zoledronate. Cinacalcet administration (120 mg/day) resulted in a significant calcium reduction. Hypocalcemia was observed when sunitinib was added three months later and cinacalcet was stopped. Subsequently, the calcium and PTH levels normalized. After six months, we observed 20% shrinkage of the pancreatic tumor and necrosis of a liver metastasis. Cinacalcet is an allosteric activator of the calcium receptor agonist, and it is used for severe hypercalcemia in patients with primary (benign and malignant) hyperparathyroidism. In this patient, cinacalcet demonstrated a calcium lowering effect, normalized hypophosphatemia, and improved the clinical condition of the patient. The mechanism through which cinacalcet improved PTH-rp mediated hypercalcemia is still unclear, but studies have suggested that a potential mechanism is the activation of calcitonin secretion. Sunitinib is an oral multi-targeted tyrosine kinase inhibitor used to treat advanced pNETs. The hypocalcemic effects of sunitinib have not been previously described in a patient with pNET. Here, we report for the first time the successful combination of cinacalcet and sunitinib in the treatment of a pNET patient presenting with malignant hypercalcemia.
Descritores: Neoplasias Pancreáticas/tratamento farmacológico
Tumores Neuroendócrinos/tratamento farmacológico
Cinacalcete/administração & dosagem
Hipercalcemia/tratamento farmacológico
Indóis/administração & dosagem
Antineoplásicos/administração & dosagem
-Neoplasias Pancreáticas/complicações
Pirróis/administração & dosagem
Tumores Neuroendócrinos/complicações
Quimioterapia Combinada
Sunitinibe
Hipercalcemia/etiologia
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  7 / 68 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1092709
Autor: Florenzano V, Matías; Reyes C, Felipe.
Título: Tratamiento farmacológico en la fibrosis pulmonar idiopática: drogas modificadoras de enfermedad / Pharmacological treatment in the FPI: disease modifying drugs
Fonte: Rev. chil. enferm. respir;35(4):287-292, dic. 2019.
Idioma: es.
Resumo: La historia natural de la fibrosis pulmonar idiopática (FPI) es heterogénea e impredecible. Aunque el curso de la enfermedad, sin tratamiento, es inevitablemente progresiva y de mal pronóstico. Los tratamientos históricos han variado desde corticosteroides e inmunosupresores (azatioprina, ciclofosfamida), hasta colchicina y N-acetilcisteína. En las últimas décadas se han realizado múltiples ensayos terapéuticos fallidos. Sin embargo, desde el año 2014 en los Estados Unidos, Europa y otros países, dos drogas, denominadas terapia antifibrótica o modificadoras de la enfermedad, están aprobadas para el tratamiento de la FPI: nintedanib y pirfenidona. La terapia antifibrótica, tiene como objetivo enlentecer en hasta 50% la declinación de la función pulmonar en pacientes con FPI.

The natural history of idiopathic pulmonary fibrosis (IPF) is heterogeneous and unpredictable. The course of the disease without treatment, is inevitably progressive, with a poor prognosis. Historical treatments have varied from corticosteroids and immunosuppressants (azathioprine, cyclophosphamide), to colchicine and N-acetylcysteine. In the last decades, multiple failed therapeutic trials have been carried out. However, since 2014 in the United States, Europe and other countries, two drugs, called antifibrotic therapy or disease modifiers, are approved for the treatment of IPF: nintedanib and pirfenidone. The purpose of antifibrotic therapy is to slow down the decline in lung function in patients with IPF up to 50%.
Descritores: Piridonas/uso terapêutico
Fibrose Pulmonar Idiopática/tratamento farmacológico
Imunossupressores/uso terapêutico
Indóis/uso terapêutico
Limites: Humanos
Tipo de Publ: Guia
Guia de Prática Clínica
Responsável: CL1.1 - Biblioteca Central


  8 / 68 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-888774
Autor: Solis, R; Pezo, M; Diaz, G; Arévalo, L; Cachique, D.
Título: Vegetative propagation of Plukenetia polyadenia by cuttings: effects of leaf area and indole-3-butyric acid concentration / Propagação vegetativa de Plukenetia polyadenia por estacas: efeitos de área foliar e concentração de ácido indol-3-butírico
Fonte: Braz. j. biol;77(3):580-584, July-Sept. 2017. tab, graf.
Idioma: en.
Resumo: Abstract The seeds of Plukenetia polyadenia have high levels of unsaturated fatty acids and are used as medicine and food for native people in the Peruvian and Brazilian Amazon. The objective of this study was to develop a method for vegetative propagation of Plukenetia polyadenia by rooting of cuttings. The experiment was laid out in a randomized complete block design with 12 treatments and 3 replications of 8 cuttings, in a 3 × 4 factorial arrangement. The factors were: 3 levels of leaf area (25, 50 and 75%) and 3 indole-3-butyric acid - IBA concentrations (9.84, 19.68 and 29.52mM) and a control without IBA. Data were submitted to analysis of variance and means were compared by Tukey test at 5% probability. Our results show that the use of cuttings with 50% of leaf area and treatment with 29.52mM of IBA induced high percentages of rooting (93%) and the best root formation. Vegetative propagation of Plukenetia polyadenia by cuttings will be used as a tool to conserve and propagate germplasm in breeding programs.

Resumo As sementes de Plukenetia polyadenia têm altos níveis de ácidos graxos insaturados e são utilizadas como medicamentos e alimentos para as pessoas nativas da Amazônia Peruana e Brasileira. O objetivo do trabalho foi desenvolver um método de propagação vegetativa de Plukenetia polyadenia por meio do enraizamento de estacas em câmeras de sub-irrigação. Foi utilizado um delineamento de blocos ao acaso com 12 tratamentos e 3 repetições de 8 estacas, e esquema fatorial 3 × 4. Os fatores foram: 3 níveis de área foliar (25, 50 e 75%) e 3 doses de ácido indol-3-butírico - AIB (9,84; 19,68 e 29,52mM) e um controle sem AIB. Os dados foram submetidos à análise de variância e as médias foram comparadas pelo teste de Tukey a 5% de probabilidade. A maior taxa de enraizamento de estacas (93%) foi obtida com 29,52mM de AIB como indutor hormonal e estacas com área foliar de 50%. A propagação vegetativa de Plukenetia polyadenia por estacas será usada como ferramenta para conservar e propagar germoplasma em programas de melhoramento.
Descritores: Reguladores de Crescimento de Plantas/farmacologia
Reprodução Assexuada
Euphorbiaceae/crescimento & desenvolvimento
Melhoramento Vegetal/métodos
Indóis/farmacologia
-Folhas de Planta/anatomia & histologia
Responsável: BR1.1 - BIREME


  9 / 68 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1040279
Autor: Morais, António.
Título: Idiopathic pulmonary fibrosis: accurate diagnosis and early treatment / Fibrose pulmonar idiopática: precisão diagnóstica e tratamento precoce
Fonte: J. bras. pneumol;45(5):e20190353, 2019.
Idioma: en.
Descritores: Fibrose Pulmonar Idiopática
-Brasil
Indóis
Limites: Humanos
Tipo de Publ: Comentário
Editorial
Responsável: BR1.1 - BIREME


  10 / 68 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1040274
Autor: Pereira, Carlos Alberto de Castro; Baddini-Martinez, José Antonio; Baldi, Bruno Guedes; Jezler, Sérgio Fernandes de Oliveira; Rubin, Adalberto Sperb; Alves, Rogerio Lopes Rufino; Zonzin, Gilmar Alves; Quaresma, Manuel; Trampisch, Matthias; Rabahi, Marcelo Fouad.
Título: Segurança e tolerabilidade de Nintedanibe em pacientes com fibrose pulmonar idiopática no Brasil / Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
Fonte: J. bras. pneumol;45(5):e20180414, 2019. tab, graf.
Idioma: pt.
Resumo: RESUMO Objetivo Ensaios clínicos mostraram que 150 mg de Nintedanibe duas vezes ao dia reduzem a progressão da doença em pacientes com Fibrose Pulmonar Idiopática (FPI), com um perfil de efeitos adversos que é controlável para a maioria dos pacientes. Antes da aprovação do Nintedanibe como tratamento para a FPI no Brasil, um Programa de Acesso Expandido (PEA) foi iniciado para fornecer acesso precoce ao tratamento e avaliar a segurança e a tolerância do Nintedanibe para este grupo de pacientes. Métodos Foram elegíveis para participar da PEA pacientes com diagnóstico de FPI nos últimos 5 anos, com capacidade vital forçada (CVF) ≥ 50% do previsto e capacidade de difusão dos pulmões para monóxido de carbono (DLco) 30%-79% do previsto. Os pacientes receberam Nintedanibe 150 mg, 2 vezes ao dia (bid). As avaliações de segurança incluíram eventos adversos que levaram à suspensão permanente do Nintedanibe e eventos adversos graves. Resultados O PEA envolveu 57 pacientes em 8 centros. A maioria dos pacientes era do sexo masculino (77,2%) e brancos (87,7%). No início do estudo, a média de idade foi de 70,7 (7,5) anos e a CVF foi de 70,7 (12,5%) do previsto. A média de exposição ao Nintedanibe foi de 14,4 (6,2) meses; a exposição máxima foi de 22,0 meses. Os eventos adversos frequentemente relatados pelo pesquisador como relacionados ao tratamento com Nintedanibe foram diarreia (45 pacientes, 78,9%) e náusea (25 pacientes, 43,9%). Os eventos adversos levaram à suspensão permanente do Nintedanibe em 16 pacientes (28,1%) que passaram por um evento adverso grave. Conclusões No PEA brasileiro, o Nintedanibe apresentou um perfil aceitável de segurança e tolerância em pacientes com FPI, condizendo com dados de ensaios clínicos.

ABSTRACT Objective Clinical trials have shown that nintedanib 150 mg twice daily (bid) reduces disease progression in patients with idiopathic pulmonary fibrosis (IPF), with an adverse event profile that is manageable for most patients. Prior to the approval of nintedanib as a treatment for IPF in Brazil, an expanded access program (EAP) was initiated to provide early access to treatment and to evaluate the safety and tolerability of nintedanib in this patient population. Methods Patients with a diagnosis of IPF within the previous five years, forced vital capacity (FVC) ≥ 50% predicted and diffusing capacity of the lungs for carbon monoxide (DLco) 30% to 79% predicted were eligible to participate in the EAP. Patients received nintedanib 150 mg bid open-label. Safety assessments included adverse events leading to permanent discontinuation of nintedanib and serious adverse events. Results The EAP involved 57 patients at eight centers. Most patients were male (77.2%) and white (87.7%). At baseline, mean (SD) age was 70.7 (7.5) years and FVC was 70.7 (12.5) % predicted. Mean (SD) exposure to nintedanib was 14.4 (6.2) months; maximum exposure was 22.0 months. The most frequently reported adverse events considered by the investigator to be related to nintedanib treatment were diarrhea (45 patients, 78.9%) and nausea (25 patients, 43.9%). Adverse events led to permanent discontinuation of nintedanib in 16 patients (28.1%). Sixteen patients (28.1%) had a serious adverse event. Conclusion In the Brazilian EAP, nintedanib had an acceptable safety and tolerability profile in patients with IPF, consistent with data from clinical trials.
Descritores: Fibrose Pulmonar Idiopática/tratamento farmacológico
Indóis/administração & dosagem
-Aspartato Aminotransferases/análise
Fatores de Tempo
Vômito/induzido quimicamente
Algoritmos
Brasil
Capacidade Vital/efeitos dos fármacos
Reprodutibilidade dos Testes
Resultado do Tratamento
Inibidores de Proteínas Quinases/administração & dosagem
Inibidores de Proteínas Quinases/efeitos adversos
Diarreia/induzido quimicamente
Tolerância a Medicamentos
Doença Hepática Induzida por Substâncias e Drogas/etiologia
Transaminases/análise
Indóis/efeitos adversos
Náusea/induzido quimicamente
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Tipo de Publ: Ensaio Clínico
Responsável: BR1.1 - BIREME



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde